Physician profile
Sunena Argo
NPI 1467660217
$15,185.45
in general payments reported to CMS, 2019-2025
30 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,882 · 2020: $805 · 2021: $371 · 2022: $9,668 · 2023: $175 · 2024: $72.02 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.14 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $8,954.64 | 2022-2024 | Xolair |
| Astrazeneca Uk Limited | $1,685.47 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $1,267.15 | 2019-2025 | Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $526.39 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $421.13 | 2019-2025 | Dupixent |
| Csl Behring | $301.57 | 2019-2025 | Andembry |
| Genzyme Corporation | $239.64 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $227.57 | 2021-2022 | |
| Genentech USA, INC. | $211.14 | 2019-2025 | Xolair |
| Pfizer INC. | $211.07 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.53 | 2021-2025 | Cuvitru |
| Ars Pharmaceuticals Operations, INC. | $194.30 | 2025 | Neffy |
| Organon LLC | $148.86 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $138.25 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.10 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $100.54 | 2019-2022 | |
| Amgen INC. | $45.61 | 2021-2025 | Tezspire |
| Encore Dermatology INC. | $31.28 | 2019-2020 | |
| Grifols USA, LLC | $19.97 | 2023 | Xembify |
| Abbvie INC. | $18.76 | 2022 | |
| Leo Pharma INC. | $18.19 | 2022 | |
| Optinose US, INC. | $17.97 | 2021 | |
| Siemens Medical Solutions USA, INC. | $17.49 | 2025 | Immulite 1000 Immunoassay System |
| Alk-Abello, INC | $14.72 | 2022 | |
| Merck Sharp & Dohme LLC | $14.52 | 2019 | |
| Blueprint Medicines Corporation | $14.09 | 2022 | |
| Shire North American Group INC | $13.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.45 | 2021 | |
| Aytu Biopharma, INC. | $11.39 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunena Argo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.